UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Seeking Alpha / 1 hour from now 1 Views

As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035
Read more

Comments